SEC Form SC 13G/A filed by ICON plc (Amendment)

$ICLR
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Get the next $ICLR alert in real time by email
SC 13G/A 1 formsc13ga.htm FORM SC 13G/A WCM Investment Management: Form SC 13G/A - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 9)*

ICON PLC

(Name of Issuer)

 

Common

(Title of Class of Securities)

 

G4705A100

(CUSIP Number)

 

December 31, 2023

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 [X]  Rule 13d-1(b)

 [_]  Rule 13d-1(c)

 [_]  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


SCHEDULE 13G

CUSIP No.           G4705A100


1

Names of Reporting Persons

WCM Investment Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)  [ ]
(b)  [ ]

3

Sec Use Only

 

4

Citizenship or Place of Organization

Delaware

Number of
Shares
Beneficially
Owned by Each
Reporting Person
With:

5

Sole Voting Power

6,869,881

6

Shared Voting Power

0

7

Sole Dispositive Power

6,869,881

8

Shared Dispositive Power

0

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,869,881

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

[ ]

11

Percent of class represented by amount in row (9)

8.3%

12

Type of Reporting Person (See Instructions)

IA



Item 1. 

(a) Name of Issuer: ICON PLC

(b) Address of Issuer's Principal Executive Offices: SOUTH COUNTY BUSINESS PARK, LEOPARDSTOWN DUBLIN 18 IRELAND

Item 2. 

(a) Name of Person Filing: WCM Investment Management, LLC

(b) Address of Principal Business Office or, if None, Residence:  281 Brooks Street, Laguna Beach, California 92651

(c) Citizenship: Delaware

(d) Title and Class of Securities: Common

(e) CUSIP No.: G4705A100

Item 3.  If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) [_] Broker or dealer registered under Section 15 of the Act;

(b) [_] Bank as defined in Section 3(a)(6) of the Act;

(c) [_] Insurance company as defined in Section 3(a)(19) of the Act;

(d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;

(e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

(k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4. Ownership


(a) Amount Beneficially Owned:   6,869,881

(b) Percent of Class:  8.3%

(c) Number of shares as to which such person has:

 (i) Sole power to vote or to direct the vote: 6,869,881

 (ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 6,869,881

(iv) Shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [    ].

Item 6. Ownership of more than Five Percent on Behalf of Another Person.

Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

Item 8. Identification and classification of members of the group.

Item 9. Notice of Dissolution of Group.

Item 10. Certifications.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  January 30, 2024

/s/ Signature

Name/Title David J. Joerger, Chief Compliance Officer

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).


Get the next $ICLR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ICLR

DatePrice TargetRatingAnalyst
3/21/2025$250.00 → $200.00Buy → Neutral
Goldman
1/7/2025$263.00Outperform
RBC Capital Mkts
10/24/2024$340.00Outperform → Neutral
Robert W. Baird
10/14/2024Neutral
Redburn Atlantic
9/18/2024$379.00Outperform
Leerink Partners
6/6/2024$370.00Buy
Goldman
12/15/2023$357.00Buy
Truist
9/13/2023$306.00Outperform
TD Cowen
More analyst ratings

$ICLR
Press Releases

Fastest customizable press release news feed in the world

See more
  • BetterInvesting™ Magazine Update on Lowe's Cos. (NYSE: LOW) and ICON PLC (NASDAQ: ICLR)

    TROY, Mich., March 24, 2025 /PRNewswire/ -- Lowe's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Lowe's Cos. (NYSE:LOW) as worthy of further study and has named the company its "Stock to Study" for the June/July 2025 double issue for investors' informational and educational use. The fundamental data is eye-opening; investors can view Lowe's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors, at: https://ssg.betterinvesting.org/trial/ssgplus/?ticker=LOW. A full

    $ICLR
    $LOW
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    RETAIL: Building Materials
    Consumer Discretionary
  • ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review

    Adoption allows ICON to take full advantage of the Medidata "Data Experience," leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ:ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will immediately begin utilizing Medidata Clinical Data Studio on its studies, differentiating ICON as the first large CRO to fully infuse this technology into its clinical workflows. The integration of Clinical Data Studio into ICON's service offerings helps unlock the full

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • ICON plc to Present at Upcoming Investor Conferences

    ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025 at 8.00 am ET and at the Barclays 27th Annual Global Healthcare Conference on Thursday, March 13, 2025 at 8.30 am ET. Any changes to these events and links to the live webcasts will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$ICLR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ICLR
SEC Filings

See more

$ICLR
Leadership Updates

Live Leadership Updates

See more
  • ICON Announces Appointment of Chief Operating Officer

    ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • ICON Announces Appointment of New Chief Financial Officer

    ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$ICLR
Financials

Live finance-specific insights

See more
  • ICON Reports Fourth Quarter and Full Year 2024 Results

    Highlights Net business wins in the quarter of $2,413 million; a net book to bill in the quarter of 1.18. Full year net business wins of $9,974 million; a net book to bill of 1.20. Closing backlog of $24.7 billion, an increase of 1.4% on quarter three 2024 and 8.3% on quarter four 2023. Quarter four revenue of $2,041.1 million, representing a decrease of 1.2% on prior year revenue. Full year revenue of $8,282 million representing a year on year increase of 2.0%. Quarter four adjusted EBITDA of $422.6 million or 20.7% of revenue, an increase of 0.9% on quarter three 2024. Full year adjusted EBITDA of $1,735.8 million or 21.0% of revenue, representing a year on year increase of 2.5%.

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call

    ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 results after the market closes on Wednesday, February 19, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 20, 2025 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • ICON Reports Third Quarter 2024 Results

    Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an increase of 2.1% on quarter two 2024 and 9.4% on quarter three 2023. Quarter three revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue. GAAP net income for the quarter of $197.1 million or $2.36 per diluted share, an increase of 19.8% on quarter three 2023 diluted earnings per share. Quarter three adjusted net income was $279.2 million or $3.35 per diluted share, an increase of 1.5% on quarter three 2023 adjusted diluted earnings

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$ICLR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more